NewLink’s HyperAcute Program In Limbo After Pancreatic Trial Blow-Up
Company says it is evaluating what to do with its HyperAcute vaccine candidates in various tumor types, as focus shifts toward IDO programs.
You may also be interested in...
Patient advocacy group is spearheading the genomics-driven trial, which will assess if stratification may finally be possible in pancreatic cancer.
The year-on-year growth rate of pancreatic cancer drug sales will be around 10% until peaking at around $1bn in 2023. The growth will be driven primarily by strong uptake of Celgene's Abraxane (nab-paclitaxel albumin bond) for the treatment of advanced pancreatic cancer, according to a recent forecast by Datamonitor Healthcare.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.